Newsfeeds - Spark Newswire

3 minute read

Zai Lab And Blueprint Medicines Announce Strategic Collaboration And License Agreement For BLU-945 And BLU-701 In Greater China; Blueprint Medicines To Receive $25M Upfront Payment, Up To $590M In Potential Future Milestone Payments

Today, 5:16 AM

Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) and Blueprint Medicines Corporation (NASDAQ:BPMC) today announced an exclusive collaboration and license agreement for the development and commercialization of BLU-945 and

BPMC

1 minute read

Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $111

By Benzinga Newsdesk

Today, 5:16 AM

Morgan Stanley maintains Blueprint Medicines (NASDAQ:BPMC) with a Equal-Weight and raises the price target from $96 to $111.

BPMC

4 minute read

The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug

By Shanthi Rexaline

Today, 5:16 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ALDX

19 minute read

Earnings Scheduled For October 28, 2021

By Benzinga Insights

Today, 5:16 AM

Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million.

AAPL

4 minute read

The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More

By Shanthi Rexaline

Today, 5:16 AM

Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength.

ABBV

1 minute read

Blueprint Medicines Q2 EPS $(1.86), Inline, Sales $27.30M Beat $19.01M Estimate

By Benzinga Newsdesk

Today, 5:16 AM

Blueprint Medicines (NASDAQ:BPMC) reported quarterly losses of $(1.86) per share which met the analyst consensus estimate. This is a 18.42 percent increase over losses of $(2.28) per share from the same period last year.

BPMC

22 minute read

Earnings Scheduled For July 29, 2021

By Benzinga Insights

Today, 5:16 AM

Companies Reporting Before The Bell • Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter.

5 minute read

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer’s Conference, IPOs and More

By Shanthi Rexaline

Today, 5:16 AM

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start to the pharma reporting season.

ABBV

5 minute read

The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs

By Shanthi Rexaline

Today, 5:16 AM

Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries.

ABBV

1 minute read

Wedbush Maintains Outperform on Blueprint Medicines, Lowers Price Target to $130

By Benzinga Newsdesk

Today, 5:16 AM

Wedbush analyst Liana Moussatos maintains Blueprint Medicines (NASDAQ: BPMC) with a Outperform and lowers the price target from $136 to $130.Wedbush analyst Liana Moussatos maintains Blueprint Medicines (NASDAQ:BPMC) with a Outperform and lowers the

BPMC